In the initial eight hypoparathyroidism participants completing four weeks of extension follow-up, all discontinued standard care while receiving TransCon PTH.
In plain wordsIn the initial eight hypoparathyroidism participants completing four weeks of extension follow-up, all discontinued standard care while receiving TransCon PTH.
- Peptide
- Palopegteriparatide
- Outcome
- Not applicableStandard-care discontinuation
- Study
n = 8
- Outcome group
- Supplement Requirements · Endocrine and hormones
- Studied dose
- Dose not stated
Source sentences
Preliminary diary data on the initial 8 subjects completing 4 weeks of follow-up in the extension trial shows that all have discontinued SoC.
2 context sentences(design, population, supporting numbers)
Phase 2 Design: PaTH Forward is a global phase 2 trial evaluating the safety, tolerability, and efficacy of TransCon PTH in adult subjects with HP.
After four weeks, all subjects enter an open-label extension period with the opportunity to receive TransCon PTH individually optimized to doses of 6 to 30 µg daily to evaluate long-term safety and efficacy.